← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Rocket Pharmaceuticals RCKT $251M	51	-16	-24%	$15M
27	27 Cartesian Therapeutics RNAC $199M	48	+2	+4%	$235M
28	28 Cellectis CLLS $111M	41	+1	+3%	$136M
29	29 Neurogene NGNE $482M	40	+1	+3%	$314M
30	30 CRISPR Therapeutics CRSP $4.95B	39	+4	+11%	$155M
31	31 Vericel Corp VCEL $2.11B	39	-3	-7%	$36.6M
32	32 uniQure QURE $1.49B	34	-5	-13%	$47.5M
33	33 Pluri PLUR $12.1M	32	+3	+10%	$5.63M
34	34 DELISTED BRAINSTORM CELL THERAPUTC BCLI	26	0	0%	$9.23M
35	35 DELISTED Carisma Therapeutics CARM	26	-1	-4%	$2.27M
36	PTE 36 DELISTED PolarityTE, Inc. Common Stock PTE	24	+6	+33%	$11.4M
37	37 Opus Genetics IRD $332M	23	-10	-30%	$10.2M
38	38 Ocugen OCGN $277M	22	-3	-12%	$20.2M
39	ONCS 39 DELISTED OncoSec Medical Incorporated ONCS	20	-1	-5%	$2.26M
40	40 Capricor Therapeutics CAPR $412M	18	-3	-14%	$630K
41	ATNX 41 DELISTED Athenex, Inc. Common Stock ATNX	16	+16	–	$9.25M
42	42 Mesoblast MESO $1.8B	16	+3	+23%	$20.1M
43	43 DELISTED BioLife Solutions BLFS	15	0	0%	$813K
44	44 Imunon IMNN $5.89M	15	-2	-12%	$1.28M
45	45 Enlivex Ltd ENLV $4.36M	9	-2	-18%	$211K
46	46 Eterna Therapeutics ERNA $2.39M	9	+1	+13%	$5.36M
47	47 Benitec Biopharma BNTC $297M	5	+4	+400%	$74K
48	48 Marker Therapeutics MRKR $15M	5	-1	-17%	$75K
49	CYAD 49 DELISTED Celyad Oncology SA American Depositary Shares CYAD	4	-2	-33%	$16M
50	50 DELISTED Scorpius Holdings, Inc. SCPX	3	0	0%	$1.9M